Status:
COMPLETED
Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study
Lead Sponsor:
Karadeniz Technical University
Conditions:
Tocilizumab
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Although its safety and efficacy in the COVID-19 patient population are still unclear, tocilizumab is one of treatment. Tocilizumab is a U.S. Food and Drug Administration approved IL-6 receptor antago...
Detailed Description
With this study, the investigators will evaluate the efficacy of Tocilizumab, an IL-6 antagonist administered in the early period in intensive care patients with COVID-19 pneumonia followed by hypoxic...
Eligibility Criteria
Inclusion
- All patients were admitted to intensive care unit, diagnosed with COVID-19 pneumonia
Exclusion
- Patients who require mechanical ventilation in intensive care admission
- Cases who received tocilizumab after being intubated during follow-up even though they were not intubated at admission
- patients for whom tocilizumab is contraindicated
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT04893031
Start Date
March 1 2020
End Date
April 1 2021
Last Update
May 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karadeniz Technical University
Trabzon, Turkey (Türkiye), 61080